ipo is the sole category represented across all 1 tracked stories. Insulet is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Tandem Diabetes Care, all published on March 6, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Tandem Diabetes Care
ipo is the sole category represented across all 1 tracked stories. Insulet is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Tandem Diabetes Care, all published on March 6, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Tandem Diabetes Care. Shared-story counts are live from our verified record — not editorial picks.
Medtronic’s diabetes subsidiary, MiniMed Group Inc., has priced its initial public offering at $20.00 per share, successfully raising $560 million. The offering of 28 million shares comes in below initial valuation targets but marks a significant strategic pivot for parent company Medtronic plc.